Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Individualizing Ovarian Cancer Care With Current and Emerging Practice-Changing Clinical Data
  • CME
  • CE

Credits Available
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: October 15, 2021 Expiration: October 14, 2022
Start Activity
Provided by Clinical Care Options, LLC in partnership with Smart Patients.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 
Supported by educational grants from
AstraZeneca
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Eloise Chapman-Davis, MD, FACOG

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan individualized treatment strategies for patients with cervical, endometrial, and ovarian cancers that incorporate novel therapies and combination strategies
  • Evaluate current and emerging practice-changing clinical data on checkpoint inhibitors and PARP inhibition as single-agent or combination therapies in cervical, endometrial, and ovarian cancer

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Eloise Chapman-Davis, MD, FACOG

Gynecologic Oncologist
Associate Professor of OB/GYN
Department of OB/GYN
Division of Gynecologic Oncology
Weill Cornell Medicine-NewYork Presbyterian Hospital
New York, New York

Eloise Chapman-Davis, MD, FACOG, has no relevant conflicts of interest to report.

Staff

Jerfiz Constanzo, PhD, MBA
Scientific Director
Jerfiz D. Constanzo, PhD, MBA, has no relevant conflicts of interest to report.
Kara Nyberg, PhD

Editorial Contributor

Kara Nyberg, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to disclose.
Kimberly J. Halla, MSN, FNP-C

Family Nurse Practitioner
Arizona Oncology
Phoenix, Arizona

Kimberly J. Halla, MSN, FNP-C, has disclosed that she has received consulting fees from GlaxoSmithKline, Merck, and Seattle Genetics.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for oncologists, oncology nurses, oncology pharmacists, and other healthcare providers who care for patients with gynecologic malignancies.

Goal

The goal of this activity is to educate oncologists, oncology nurses, pharmacists, and other healthcare professionals about recent developments in the care of gynecologic malignancies and raise awareness of disparities in care to optimally individualize therapy for this patient population.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-220-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 15, 2021, through October 14, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Individualizing Ovarian Cancer Care With Current and Emerging Practice-Changing Clinical Data
  • CME
  • CE

Loading...
Listen to this interactive virtual presentation by Dr. Eloise Chapman-Davis discussing how to individualize care for women with ovarian cancer based on current and emerging clinical data.
Eloise Chapman-Davis, MD, FACOG
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: October 15, 2021 Expiration: October 14, 2022

Related Content

Downloadable short slideset from CCO on recognizing and managing ocular toxicities associated with antibody–drug conjugates.

Asim V. Farooq, MD Joann Kang, MD Paul G. Richardson, MD Released: November 29, 2021

Podcast episode with expert insights on important trial data for ovarian and endometrial cancers from the ESGO 2021 annual meeting, from Clinical Care Options (CCO)

Nicole Concin, MD, PhD Released: November 23, 2021

Virtual presentation by Angeles Alvarez Secord, MD, MHSc, on individualizing care for women with cervical cancer based on current and emerging clinical data, from Clinical Care Options (CCO)

Angeles Alvarez Secord, MD, MHSc Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 22, 2021 Expired: November 21, 2022

Virtual presentation by Angeles Alvarez Secord, MD, MHSc, on patient underrepresented and minority women enrollment on clinical trials for cervical cancer, from Clinical Care Options (CCO)

Angeles Alvarez Secord, MD, MHSc Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 16, 2021 Expired: November 15, 2022
Provided by Clinical Care Options, LLC in partnership with Smart Patients.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 
Supported by educational grants from
AstraZeneca
GlaxoSmithKline
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue